Internal Reference Number: FOI_8007
Date Request Received: 17/06/2024 00:00:00
Date Request Replied To: 21/06/2024 00:00:00
This response was sent via: By Email
Request Summary: Ophthalmology drugs
Request Category: Private Individuals
| Question Number 1: I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated. For the 4 months from January to April 2024, how many patients received the following intra-vitreal treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab - Ongavia | |
| Answer To Question 1: Aflibercept 551 Bevacizumab <5 Brolucizumab 0 Dexamethasone 13 Faricimab 294 Ranibizumab – Lucentis <5 Ranibizumab – Ongavia 0 | |
| Question Number 2: For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab - Ongavia | |
| Answer To Question 2: Aflibercept 55 Bevacizumab <5 Brolucizumab 0 Dexamethasone <5 Faricimab 20 Ranibizumab – Lucentis 0 Ranibizumab – Ongavia 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at ÃÛÌÒÓ°Ïñ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ÃÛÌÒÓ°Ïñ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
